数据
资源
版本对比
免费注册
预约演示
免费注册
leon-nanodrugs appoints Dr. Hans Frickel as Chief Executive Officer
2023-07-20
·
BioSpace
高管变更
July 18, 2023 – Munich (Germany) –
leon-nanodrugs GmbH
(“
LEON
”), the leading enabler of nano technology for the pharmaceutical industry, announced today the appointment of Dr. Hans Frickel as CEO, effective July 1, 2023. Dr. Hans Frickel, a trained pharmacist and industrial manager, brings more than 20 years of experience in strategic and operational leadership roles across the entire value chain of pharmaceuticals and medical devices. Prior to joining
LEON
, he served as Managing Director at
R‑Biopharm
and held several senior operational management roles at
BioNTech
,
Evonik
,
Midas Pharma
,
Procter & Gamble
and
Merck
. Dr. Hubert Birner, Chairman of the
LEON
Supervisory Board, said: “On behalf of the Supervisory Board, I am delighted to welcome Dr. Hans Frickel to
LEON
. With his extensive expertise in different areas of modern drug manufacturing, including plant management and QC, as well as a strong track record in strategy and governance, he is an ideal fit to take
LEON
to the next stage. On behalf of the Supervisory Board I also would like to thank our interim CEO and CFO Christian Nafe, our CSO Dr. Setu Kasera and their team for their tremendous work in driving our technology towards commercialization and for the great progress that has been achieved to date.” “I am excited to join
LEON
as we work to transform nanomedicine manufacturing,” said Dr. Hans Frickel, CEO of
LEON
. “I am impressed with the team’s knowledge and dedication in working to create added value across the nano formulation processing chain. I truly believe that
LEON
’s NANO devices will significantly improve development and manufacturing for current and future standardized and personalized cell & gene therapies at CDMOs, biotech and pharma companies.” ABOUT
LEON
-NANODRUGS
leon-nanodrugs GmbH
(“
LEON
”) is a pharmatech company specializing in the development and marketing of devices for the encapsulation of genetic material and other active substances into nanodrug carriers, such as lipid nanoparticles (LNPs). The Munich-based private company builds its innovative solutions based on its proprietary FR-JET Technology, enabling pharma companies and small biotechs as well as CDMOs to optimize nanomedicine manufacturing and take full advantage of the significant progress being made in advanced therapies.
LEON
's GMP-compliant, aseptic devices NANOme and NANOus increase efficiency in the production of nano drug carriers and are suitable for both clinical-scale and commercial production. In addition to its product offering,
LEON
will provide in-house lab capacity for process development with its own devices. For further information, please visit and follow us on LinkedIn and Twitter. CONTACT: MEDIA INQUIRIES:
leon-nanodrugs GmbH
Maja Tinko-Kuhar, Marketing Manager Phone: +49-89-41424889-98 e-mail: m.tinko-kuhar@leon-nanodrugs.com MC Services AG Katja Arnold / Eva Bauer Phone: +49-89-210228-0 e-mail: leon-nanodrugs@mc-services.eu Dr. Hans Frickel, CEO of
leon-nanodrugs GmbH
, ©
LEON
For a high-res picture please contact leon-nanodrugs@mc-services.eu.
更多内容,
请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点,如有版权侵扰或错误之处,请及时联系我们,我们会在24小时内配合处理。
机构
leon-nanodrugs GmbH
Guangdong De Leon Biotechnology Co., Ltd.
R-Biopharm AG
[+5]
适应症
-
靶点
-
药物
-
标准版
¥
16800
元/账号/年
新药情报库 | 省钱又好用!
立即使用
热门报告
全球潜力靶点及FIC产品研究调研报告
智慧芽生物医药
肿瘤领域药物开发早期热门靶点研究报告(AACR 2023-2024)
智慧芽生物医药
siRNA药物Amvuttra专利调研实务指南
智慧芽生物医药
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台,助您全方位提升您的研发与决策效率。
开始免费试用
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台,以API或者数据包形式对外开放,助您更加充分利用智慧芽新药情报信息。
试用数据服务